• Vaccine Name: β-propiolactone-inactivated SARS-CoV vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Inactivated or "killed" vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: whole virus (See et al., 2006)
• Immunization Route: subcutaneous injection
• Description: whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine (See et al., 2006)

Mouse Response

• Host Strain: 129S6/SvEv
• Host age: 6 weeks (See et al., 2006)
• Host gender: Female (See et al., 2006)
• Vaccination Protocol: Vaccination at 0 weeks and 4 weeks (See et al., 2006)
• Immune Response: A 19-fold difference (P=0·02) in total SARS-CoV-specific IgG levels and lung viral titers were reduced by 4 logs to undetectable levels compared with titers observed in the PBS control on day 3 post-challenge, vaccinated animals showed significantly higher levels (P=0·002) of IFN-γ than control animals (See et al., 2006).
• Challenge Protocol: Vaccination at 0 weeks and 4 weeks challenged by SARS-CoV-Tor2 at week 7 (See et al., 2006)